Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer.
Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, Harvey M, Neveu B, Loehr J, Bergeron A, Fradet Y, Lacombe L, Riopel J, Latulippe É, Atallah C, Shum M, Lambert JP, Pouliot F, Pelletier M, Audet-Walsh É.
Gonthier K, et al. Among authors: weidmann c.
Mol Oncol. 2023 Oct;17(10):2109-2125. doi: 10.1002/1878-0261.13441. Epub 2023 Jul 19.
Mol Oncol. 2023.
PMID: 37086156
Free PMC article.